Neuroscience and AI Optimized (NAIO™) platform
The Neuroscience and AI Optimized (NAIO™) platform was developed to achieve the scale, automation, and integration of advanced computational neuroimaging technologies into enterprise scale infrastructure for CNS drug discovery. By integrating and automating multi-modal computational neuroimaging processing and analytics, NAIO™ allows teams to quantify animal and human neural and endpoint data across the CNS drug discovery pipeline - from biomarker discovery to target validation to patient selection. Collectively, the NAIO™ platform removes barriers for integrating advanced neuroimaging solutions across the CNS drug discovery lifecycle.
How we collaborate
Biotech companies
Organizations in need of computational neuroimaging infrastructure to support decision making
Large consortia
Academic and public-private institutions looking to standardize imaging pipelines and analytics
Innovation partners
Partners who share our vision for advanced, AI-enabled, computational CNS neuroimaging solutions
Individualized brain therapeutics
The core problem: Inefficient integration of neuroimaging data creates decision barriers in neuroscience therapeutic development
- Manual, specialist-dependent imaging workflows are difficult to document, reproduce and transfer
- Fragmented tools prevent multimodal integration within a single enterprise ecosystem
- Data ingestion and orchestration slow ongoing progress of neuroimaging deployment during and after clinical trials
- Processing bottlenecks can render large datasets unusable, slowing down discovery and innovation
- The absence of a unified computational infrastructure makes it challenging to link imaging to biology, symptoms or targets
NAIO™ is an enterprise-grade, computational neuroimaging ecosystem that improves decision making across neuroscience therapeutic development
- Scalable, standardized pipelines for MR, PET, EEG, human gene expression and symptom analytics – reproducible across studies and sites
- A neuroimaging data lake that unifies imaging, phenotypes and brain-wide gene expression data into one integrated system
- Decision-grade analytics and readouts for target engagement verification, functional pharmaco-dynamic signal mapping and patient stratification